Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

Soman, Ashish; Honeybourne, D.; Andrews, J. M.; Jevons, G.; Wise, R.

doi:10.1093/jac/44.6.835

Cited by 135 publications

(101 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19][20][21][22][23] The volume of ELF contained in each BALf sample was determined by the urea dilution method. Urea diffuses freely throughout the body with the concentration in plasma equal to that in other body fluids.…”

Section: Estimation Of Epithelial Lining Fluid (Elf) Volumes and Detementioning

confidence: 99%

“…RME was performed non-surgically and aimed for a minimal expansion of 7 mm. The patients were sorted into paediatric (age <13), adolescent (age [13][14][15][16][17], and adult (age >17) groups. Total nasal airflow was measured at driving pressures of 75 and 150 Pa, both before and 10 minutes after topical oxymetazoline.…”

Section: P1-64mentioning

confidence: 99%

“…Sherrill et al in a longitudinal study reported that, a significant inverse association was found between total serum IgE and FEV1/FVC (15). They suggested that higher IgE levels may indicate the presence of a disease process that may involve inflammation and/or other mechanisms related to IgE production, which impair lung function over time (16). In a study Endoh et al concluded that higher serum IgE levels were correlated with lower values of FEV1, which is related to airways tonisity which possibly acts via cholinergic mechanisms (17).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Poster Abstracts

2008

Respirology

View full text Add to dashboard Cite

Background: Total serum IgE level as a marker of allergic inflammation is associated with severity of the asthma, and is targeted for treatment of it. The aim of this study was to determine the relationship between total serum IgE levels with response to routine drug treatment in acute asthma. Materials and methods: The study was carried out in 162 subjects with acute asthma. Total IgE serum, peripheral blood cell and eosinophils counts were measured. Management in all of the patients was adjusted according to the level of asthma severity, and spirometry was performed before and 2 weeks after treatment. The relationships between baseline and percentage changes of FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity), FEF25-75% (forced expiratory flow at 25 to 75% of vital capacity), peripheral white blood cell and eosinophils counts with asthma with high IgE levels (≥100 IU/ml) to those of patients with low IgE levels (<100 IU/ml) were studied cross-sectionally. Results: No relationship between percentage changes of FEV1, FVC, FEF25-75%, white blood cell count, and peripheral blood eosinophil; with high and low level of total serum IgE was seen (p = 0.89; 0.74; 0.68; 0.72; 0.44; respectively). No significant relationships between baseline predicted of FEV1, FVC, and FEF25-75% among asthma with high and low levels of total serum IgE was observed (p = 0.79; 0.69; 0.45; respectively). Conclusion: On the basis of these findings we conclude that the level of total serum IgE levels, peripheral white blood cell counts and eosinophils percent cannot be used to predict the response to anti-asthmatic drugs. Keywords: Asthma, predicting response; therapy; total serum IgE Introduction: Asthma is a condition characterized by variability in airflow obstruction, fluctuation of symptoms, and changes in the level of bronchial responsiveness and airway inflammation. Elevated serum IgE level as a marker of allergic inflammation and atopy contribute to asthma, and is considered as a potent prediction for the development of asthma. In patients with higher IgE, had a greater increase in PC20 when administered inhaler corticosteroids than those with lower IgE levels (1). Recently Moin et al. reported that in children, higher IgE levels lower the probability of hospitalization during asthmatic attack (2). It is unknown, in asthma, whether patients who do not respond well to one medication might respond to the other medication. In children with mild-to-moderate persistent asthma, a favourable response to inhaler corticosteroid was associated with higher levels of exhaled nitric oxide, total eosinophils counts, levels of serum IgE and other markers of allergic inflammation (3). Moreover, Cai et al. in a study on patients with stable mild to moderate asthma that were treated with montelukast in four-week concluded that there was not significant correlation between the clinical response and serum IgE levels (4). The percentage of patients with asthma and airway responsiveness in general population with higher IgE levels ...

show abstract

Section: Estimation Of Epithelial Lining Fluid (Elf) Volumes and Detementioning

confidence: 99%

Section: P1-64mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Poster Abstracts

2008

Respirology

View full text Add to dashboard Cite

show abstract

“…Le concentrazioni di moxifloxacina sono state misurate dopo singola dose orale di 400mg nei liquidi e tessuti polmonari di soggetti sottoposti a broncoscopia e nella mucosa dei seni nasali di pazienti trattati con 400mg/die e sottoposti ad intervento chirurgico [87,88]. Dopo singola dose orale (400mg) le concentrazioni di moxifloxacina nel secreto bronchiale, nel tessuto bronchiale e nei macrofagi alveolari raggiungono concentrazioni notevolmente più elevate di quelle sieriche anche dopo 24 ore dalla somministrazione (Figura 2).…”

Section: Farmacocineticaunclassified

“…Durante l'intervallo fra le dosi le concentrazioni nei liquidi e tessuti polmonari sono molte volte superiori alle MIC 90 dei comuni patogeni respiratori quali lo Streptococcus [87] .…”

Section: Farmacocineticaunclassified

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Eandi

2003

View full text Add to dashboard Cite

PREMESSEMoxifloxacina è un nuovo fluorochinolone di recente introduzione nell'armamentario terapeutico per il trattamento antibiotico delle infezioni delle basse ed alte vie respiratorie [1][2][3][4][5][6][7].Moxifloxacina è un 8-metossichinolone dotato di un ampio spettro d'azione antibatterico nei confronti dei batteri Grampositivi e Gram-negativi, aerobi ed anaerobi e dei patogeni atipici quali micoplasmi, legionelle e clamidie [3, 7, 8]. Questo nuovo antibiotico è tra i farmaci più potenti attualmente disponibili nei confronti dei batteri Gram-positivi, compresi lo Staphylococcus aureus meticillino-resistente e i pneumococchi, sia sensibili che resistenti alla penicillina. La moxifloxacina è attiva quanto la ciprofloxacina verso Legionella spp., ma più attiva verso Chlamydia spp. e Mycoplasma pneumoniae. Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomicoMario Eandi * Moxifloxacina manifesta minore efficacia rispetto a ciprofloxacina verso le Enterobatteriaceae e verso Pseudomonas aeruginosa. Dotata di una potente e rapida azione battericida concentrazione-dipendente verso i batteri Gram-positivi e di un marcato effetto post-antibiotico, la moxifloxacina si accumula rapidamente nei ceppi sensibili, agisce inibendo in ugual misura sia la DNA girasi sia la topoisomerasi IV e manifesta una ridotta tendenza a selezionare ceppi mutanti resistenti [1, 7].La farmacocinetica della moxifloxacina si caratterizza per la lunga emivita, circa 12 ore, per un'elevata biodisponibilità orale, un'eccellente diffusibilità tissutale extravascolare e per la scarsità di interazioni con altri farmaci [1, 7]. Il profilo di tollerabilità, simile a quello dei fluorochinoloni, si differenzia, tuttavia, per l'assenza di fototossicità [2]. ABSTRACTMoxifloxacin is a new fluorquinolone antibiotic, recently introduced among the treatment options for upper and lower airways infections. It possesses a wide antibiotic spectrum, covering the major pathogens involved in the genesis of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS). It acts in a concentration-dependent manner by inhibition of bacterial DNAgirase and topoisomerase IV, has a long biological half-life (about 12 hours), good oral bioavailability, excellent tissue diffusion and a better safety profile than other quinolones, because of the lack of phototoxicity and the scarsity of clinically significant drug interactions. The clinical results of moxifloxacin in CAP, AECB and ABS have been compared with those of available alternative antibiotics in several multicentric, double-blind studies, and the new fluorquinolone resulted at least as effective as the comparators, with similar tolerability profiles. These studies demonstrated a high correlation among the eradication of the pathogen and the clinical recovery of the patients. The pharmacodynamics, pharmacokinetics and clinical results of moxifloxacin render it one of the most attractive options for the empirical treatment of upper and lower air...

show abstract

Antitubercular Agents

Aldrich

Boshoff

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

Cited by 135 publications

References 8 publications

Poster Abstracts

Poster Abstracts

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Antitubercular Agents

Contact Info

Product

Resources

About